APA (7th ed.) Citation

G, B., SC, S., L, K. C., LA, J., SB, M., L, D., . . . V, A. (2016). The Efficacy, Safety, and Cost Benefit of Olanzapine versus Aprepitant in Highly Emetogenic Chemotherapy: A Pilot Study from South India. Chemotherapy research and practice, 2016, 3439707. https://doi.org/10.1155/2016/3439707

Chicago Style (17th ed.) Citation

G, Babu, et al. "The Efficacy, Safety, and Cost Benefit of Olanzapine Versus Aprepitant in Highly Emetogenic Chemotherapy: A Pilot Study from South India." Chemotherapy Research and Practice 2016 (2016): 3439707. https://doi.org/10.1155/2016/3439707.

MLA (9th ed.) Citation

G, Babu, et al. "The Efficacy, Safety, and Cost Benefit of Olanzapine Versus Aprepitant in Highly Emetogenic Chemotherapy: A Pilot Study from South India." Chemotherapy Research and Practice, vol. 2016, 2016, p. 3439707, https://doi.org/10.1155/2016/3439707.